Breakthrough approach enters UK clinical trials

A pioneering UK clinical trial is exploring whether small patches of donor skin could transform how doctors detect and prevent organ rejection — one of the most significant challenges in transplant medicine. The SENTINEL trial, led by researchers at University of Oxford and supported by the National Institute for Health and Care Research and NHS Blood and Transplant, is testing whether transplanting a small piece of skin alongside donor lungs can act as an early warning system for rejection.

The concept is simple but potentially transformative: because skin reacts more quickly and visibly to immune responses than internal organs, it may provide an accessible signal when the body begins to reject a transplanted lung. If successful, the approach could reduce reliance on invasive diagnostic procedures and enable earlier intervention, improving long-term survival rates for transplant patients.

Patient experience highlights potential impact

One of the first patients to participate in the trial has already provided compelling early evidence of its potential. Darren White, a lung transplant recipient from the north-east of England, received a donor skin patch on his forearm at the same time as his transplant in 2024. Three months later, he noticed a purple rash on the patch, despite feeling otherwise well.

After alerting his clinical team, a biopsy confirmed early-stage rejection. He was treated promptly with steroids, preventing further damage to the transplanted lungs. White has since said the patch was “invaluable” in identifying rejection before symptoms developed, and believes it played a critical role in protecting his transplant. His experience reflects one of the core challenges in transplant care: rejection can often progress silently until significant damage has already occurred.

Addressing a major unmet need in transplant medicine

Lung transplantation remains one of the most complex and high-risk procedures in modern medicine. Rejection rates are highest in the first three to six months after surgery, affecting up to 30% of patients. Detecting rejection currently requires frequent hospital visits and invasive tests, including bronchoscopies, lung biopsies and imaging. Despite these efforts, long-term outcomes remain challenging, with only around half of lung transplant recipients surviving beyond five years, with rejection a leading cause of mortality.

The SENTINEL trial aims to address this gap by providing a visible, minimally invasive method of monitoring the immune response.In the study, participants receive a small (approximately 10cm by 3cm) patch of skin from the same donor as the lung, transplanted onto the forearm. If rejection begins, it is expected to manifest first as visible changes such as redness or rash in the skin graft, allowing clinicians to intervene earlier.

Digital monitoring and patient-led detection

A notable feature of the trial is its potential to empower patients through self-monitoring, supported by digital tools. Participants are encouraged to observe the skin patch and report any changes, including via photographs shared with clinical teams enabling rapid assessment without immediate hospital visits. This approach aligns with broader trends in digital health, where remote monitoring and patient engagement are increasingly central to care delivery.

By combining a simple biological signal with digital communication, the model could reduce the burden on outpatient services while improving responsiveness to early warning signs. It also represents a shift towards more personalised and proactive transplant care, where patients play an active role in managing their condition.

Scaling the trial and future implications

The SENTINEL trial is expected to recruit around 152 patients across five UK specialist transplant centres and will run until 2027. Researchers will compare outcomes between patients receiving lung transplants alone and those receiving both lung and skin grafts, assessing whether the technique reduces rejection rates and improves survival. Beyond lung transplantation, the implications could extend to other organ transplants, including heart and combined heart-lung procedures. Experts suggest that if the technique proves effective, it could become a standard component of transplant surgery, offering a low-cost, scalable method for improving outcomes.

A potential paradigm shift in transplant care

The development of donor skin patches as an early warning system represents a novel intersection of surgical innovation, immunology and digital health. While further evidence is needed before widespread adoption, early results suggest the approach could address one of the most persistent challenges in transplantation: detecting rejection before irreversible damage occurs.

For patients, the benefits could be profound, reducing anxiety, minimising invasive testing and improving long-term survival. As the NHS and global health systems continue to invest in advanced therapies and precision medicine, innovations such as the SENTINEL trial highlight relatively simple ideas, supported by robust research and technology which can deliver transformative change.

‍